- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Unichem Labs Slapped Rs 1.77 Crore NPPA Notice for Alleged Overpricing of 3 Drugs

New Delhi: Unichem Laboratories Limited has received three demand notices from the National Pharmaceutical Pricing Authority (NPPA), alleging overcharging for three of its drugs over various periods between 2013 and 2018. The notices, issued under para 15 of the Drug Price Control Order (DPCO), 2013, carry a total penalty of Rs 1.77 crore.
The demand notices, dated 29th September 2025 and received by the company on 3rd October 2025, cite alleged overpricing for the following periods: July 2013 to November 2018, February 2016 to November 2018 and January 2016 to November 2018.
It is noteworthy that Unichem had sold its domestic formulation business in December 2017, which partially overlaps with the alleged period of violation.
Despite the notices, the company has assessed that the penalties are not expected to have any material impact on its financials, operations, or other business activities. Unichem Laboratories is reportedly evaluating legal options to address the NPPA’s notices.
The disclosure was made under Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, to the BSE and NSE, where the company’s shares are listed under the script codes 506690 (BSE) and UNICHEMLAB (NSE).
Pradeep Bhandari, Head – Legal & Company Secretary of Unichem Laboratories, confirmed that the company will act in accordance with the applicable legal framework.
Mpharm (Pharmacology)
Susmita Roy, B pharm, M pharm Pharmacology, graduated from Gurunanak Institute of Pharmaceutical Science and Technology with a bachelor's degree in Pharmacy. She is currently working as an assistant professor at Haldia Institute of Pharmacy in West Bengal. She has been part of Medical Dialogues since March 2021.